Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a gene-editing company’s disclosures can feel like graduate-level biology. Beam Therapeutics’ 10-K discusses base editing chemistry, while 8-Ks track trial pauses and collaboration payments—details that determine valuation yet hide in technical language. If you have ever searched "Beam Therapeutics SEC filings explained simply" and still felt lost, you are not alone.
Stock Titan turns those sprawling documents into clear insights. Our AI parses every Beam Therapeutics quarterly earnings report 10-Q filing, flags shifts in cash runway, and links pipeline milestones to revenue guidance. Need alerts on Beam Therapeutics insider trading Form 4 transactions? We stream Beam Therapeutics Form 4 insider transactions real-time so you can monitor executive stock moves before they hit the headlines. From a Beam Therapeutics annual report 10-K simplified to a Beam Therapeutics proxy statement executive compensation breakdown, each filing is auto-summarized, cross-referenced, and searchable alongside original EDGAR pages.
Use cases are practical: compare R&D spend quarter over quarter, study option grants in the Beam Therapeutics 8-K material events explained, or dive into licensing royalty terms—all without reading 300 pages. Whether you are a portfolio manager seeking "Beam Therapeutics earnings report filing analysis" or a researcher "understanding Beam Therapeutics SEC documents with AI," our platform delivers the context that drives informed decisions. Every filing, every update, right when it matters.
Filing: Amendment No. 9 to Schedule 13G filed for BEAM THERAPEUTICS INC (CUSIP 07373V105) reporting a beneficial ownership position.
Key facts: FMR LLC and Abigail P. Johnson report aggregate beneficial ownership of 15,083,498.08 shares (15.0%). FMR LLC reports sole voting power of 15,073,316 and sole dispositive power of 15,083,498.08; shared powers are 0. Abigail P. Johnson reports sole dispositive power of 15,083,498.08 and no voting power. The "Date of Event Which Requires Filing" is 06/30/2025 and the signature date is 08/05/2025. Item 10 certifies the securities were not acquired to change or influence control. Exhibits referenced: Exhibit 99 (13d-1(k)(1) agreement) and Exhibit 24 (power of attorney).
Report type: Current Report on Form 8-K dated August 5, 2025 by Beam Therapeutics Inc. (BEAM).
On August 5, 2025 the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The filing states that the information and Exhibit 99.1 are being furnished (not "filed") for purposes of the Exchange Act and are not subject to Section 18 liability except by specific reference.
Corporate details: Beam Therapeutics Inc., Delaware, principal office 238 Main Street, Cambridge, MA 02142; common stock trades as BEAM on Nasdaq Global Select Market. Form signed by John Evans, Chief Executive Officer.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
